title: BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo.
abstract: OBJECTIVE
  In spite of all the efforts and researches on anticancer therapeutics, an absolute treatment is still a myth. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In this study, for the first time, we have evaluated the anticancer effects of BCc1 nanocomplex by vitro and in vivo studies, which is designed based on the novel nanochelating technology.
  
  
  METHODS
  Human breast adenocarcinoma cell line (MCF-7) and mouse embryonic fibroblasts were used for the in vitro study. Antioxidant potential, cell toxicity, apoptosis induction, and CD44 and CD24 protein expression were evaluated after treatment of cells with different concentrations of BCc1 nanocomplex. For the in vivo study, mammary tumor-bearing female Balb/c mice were treated with different doses of BCc1 and their effects on tumor growth rate and survival were evaluated.
  
  
  RESULTS
  BCc1 decreased CD44 protein expression and increased CD24 protein expression. It induced MCF-7 cell apoptosis but at the same concentrations did not have negative effects on mouse embryonic fibroblasts viability and protected them against oxidative stress. Treatment with nanocomplex increased survival and reduced the tumor size growth in breast cancer-bearing balb/c mice.
  
  
  CONCLUSIONS
  These results demonstrate that BCc1 has the capacity to be assessed as a new anticancer agent in complementary studies.
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Somayeh
authors.initials: S
authors.lastname: Kalanaky
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Stem Cell Technology Research Center, Tehran, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Hafizi
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
authors.forename: Saideh
authors.initials: S
authors.lastname: Fakharzadeh
authors.affiliation: Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Vasei
authors.affiliation: Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Ladan
authors.initials: L
authors.lastname: Langroudi
authors.affiliation: Department of Haematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Ehsan
authors.initials: E
authors.lastname: Janzamin
authors.affiliation: Department of Immunology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Seyed Mahmoud
authors.initials: SM
authors.lastname: Hashemi
authors.affiliation: Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Khayamzadeh
authors.affiliation: Department of Haematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Masoud
authors.initials: M
authors.lastname: Soleimani
authors.affiliation: Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad Esmaeil
authors.initials: ME
authors.lastname: Akbari
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
authors.forename: Mohammad Hassan
authors.initials: MH
authors.lastname: Nazaran
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D002614:Chelating Agents / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D061986:MCF-7 Cells; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles; D018384:Oxidative Stress / Q000187:drug effects; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D002614:Chelating Agents
keywords: BCc1; cancer; nanochelating technology; nanocomplex; nanotechnology